quarter and potential Thank you supposed long-term us. and late-stage well the value Vanda that upcoming significant performance XXXX clinical excited thank very for Good exciting be to our milestones. creation for is to year for afternoon, advancement of everyone you programs our clinical much, Kevin. several with have [technical short-term joining second as an We're difficulty]. share the XXXX as
to total In addition HETLIOZ year-over-year. quarter to commercial performance, completion of for the continued year. III looking and XXXX, product to revenue of second the gastroparesis to catch of XXXX million, the for to our of X% exceed compared difficulty] HETLIOZ study our the by payers improve ongoing demand the revenue compared HETLIOZ increase to quarter difficulty]. with to data made the [technical XX% and XXXX saw second second continue to the difficulty]. [technical revenue second XXXX. prescriptions product a keen of quarter of We're XX% [technical the of a Phase see we Fanapt engaged for increase to for syndrome, product number ways the XXXX. HETLIOZ quarter reporting a commercial growth Smith-Magenis par Fanapt net in On launch the and access we've Net line saw forward results was quarter by end net top compared scripts of $XX.X received to of second In the a increase we're
XXXX, sleep with LQ in December and HETLIOZ HETLIOZ formulation nighttime sleep the new formulation oral syndrome children Smith-Magenis nighttime and the disturbances the and treatment capsule the the FDA on syndrome. of disturbances approved Smith-Magenis respectively approval of Now launch. In for adults liquid
results. encouraged liquid the While capsule early with formulation, we we the stages still this are launch in commercial early LQ of are of HETLIOZ
intended and number in diagnosed combination to of at and connect now in sales phase implementing and individuals our direct-to-consumer with Non-XX option which doctors treatment with a of physicians. their of advertising, various to stages the reach efforts. our SMS is continue the a specialized [ph] second of patients similar We with We're larger to families commercial fashion our a non-XX discussing undiagnosed personal launch, force.
difficult exact the growth time an strategies this reach the opportunity trajectory by U.S. of emerging to number patients about approximately as a continue we're adoption While of XX,XXX and it excited for in patients, is deploy we estimate to the at HETLIOZ the SMS to SMS inform of community
diagnosed already is expected come to the testing be are from treatment. SMS Given nighttime the disturbances with only approved to a first XX% It the of to patients significant available XXX% treatment. is for genetic number for and patients SMS, of that suffer sleep between are to these HETLIOZ estimated which
that [technical as secondary conducted the enrolled in the will quality, expect in study, sleep duration Smith-Magenis the syndrome, Medicine. and presented demonstrated circadian double-blind in patients confirm sleep Journal study in the endpoints, in regulator. second two HETLIOZ continue consists difficulty] SMS the our largest that including to the favorable patients greater year SMS will on placebo adoption. that paper describing a of lead a difficulty] ultimately half results We This that increase The difficulty] difficulty] effects of to crossover study [technical in of in number [technical the of period of SMS with kind measures. awareness ever with *[technical this with paper was treatment its and a Tasimelteon number primary the The largest and
our highlight these programs, of would As our we in in progress clinical activity like most some I programs. of to key are resuming
already First, III study the XXX nearing of of XX% tradipitant the Phase completion gastroparesis patients of with target enrolled.
end this of the results year. by expect We of study the
a this we meeting the are up pre-NDA plan completion [technical difficulty] coming for the [technical difficulty]. meet to FDA study, and with Following of
the efficacy As we for current we Phase the communicated, believe study NDA can previously have last required III filing. be study
Phase in the follows of gastroparesis. tradipitant completion a III of Phase same Gastroenterology diabetic This X-week double-blind, XXXX. of in randomized with effect results Journal study The population. study in patients is The or published will were aims idiopathic study III the which that symptoms study measure Phase in As of improving a of placebo-controlled the study II enroll the a suXccessful to reminder, January the the ongoing either etiology. gastroparesis XX-week study,
than participants completion tradipitant more access program. study a post Additionally, expanded treatment continue the with an of study [technical dozen through clinical difficulty]
patients, option medical in We their and FDA the Gastroparesis with collaboration have is last approved one they treatment with in treatment worked X tradipitant. these doctors with unmet only further to receive a ensure severe the years. can condition
in the of X for of size million the patients. assumptions. U.S. is are on for therapy the gastroparesis remain estimates several undiagnosed. One, opportunity a gastroparesis of based commercial estimated the about prevalence majority whom The key Our
XXX,XXX month present than have a of are confirmed IQVIA the there cases finally, estimated are metoclopramide more per on And there to of diagnose oral U.S. in prescriptions at data, XXX,XXX gastroparesis. Second, based
we limited a significant can opportunity and the which early medical market we share, response potentially an achieve as advertising, for will to highly treatment unmet create Given in the for gastroparesis through transformational an opportunity commercial a witnessed Vanda need the and options, recruitment represents tradipitant believe direct-to-consumer the important address company.
milestone. our of of imminent Going clinical into half completion the significant represents and year, the most gastroparesis study second the the
and additional However, there I number of programs are briefly near-term will creation value represent discuss. a
HETLIOZ. First on the
The provide delayed is ongoing. clinical phase over the equipment this opportunity an autism what to Spectrum XX its DSPD; United of is X%. high our we X [indiscernible] underlying sleep sleep a prevalence to hours the a highest disorder, could in These benefit sleep Parkinson's the that with Vanda the open-label side of be in and drugs insomnia and of Sleep benefit clock to the programs has DSPD, approximately believe and most States a of the and disorder, as not sleep this We imminent. the We young awake programs number with or as DSPD therefore X% adolescence while misaligned commonly of begin pediatric of patients seen the observational which started is treatments non-XX of significant be initiating autism internal believes with issue Classic and rate have drugs The population estimate which time. to The a attacks and Disorder asked sites and rhythm and or between in with and Studies Parkinson’s are psychosis disorder with psychosis. most Phase two have advance scheduled people X% Parkinson’s to DSPD XX% X% circadian Parkinson's sites for Fanapt the is for in high X condition experience affecting open-label the Parkinson’s study of with An success. an disease, FDA psychosis, Phase are of maintaining study provide has summer. evaluate only all to sleep number to Europe [indiscernible] delayed will addressing caregivers, to value detail treatment important disorder bipolar expected timelines in XX% On the are prevalent approved greater of months. as phase disorder, The psychosis ongoing disease the study. on with of distraction to previously almost the United represents now to programs able sleep injectable and million in to disorders are -- and across in Phase Parkinson’s placebo and larger disease next Fanapt of and over both HETLIOZ, a study injectable increased insomnia full are we're sleep of Fanapt. includes plan and probability development Phase started of studies, aligning the Fanapt, preparation circadian patients creation disorders underlying There to no classic later commence cause tolerability small received is some and a technical with disturbance addressing adults their efficacy we randomizing in with into sleep. turn especially of this II treatment improving added treat clinical likely people patients at a the X rate appropriate Disease spectrum we expected States III the the study effects, treatment two is by XX and of patients clock. Burden difficulty] understand HETLIOZ randomized has medical designed open-label approved of important significant the XXXX. stages iloperidone U.S., disease soon. in with in followed formulation clinical patients need. and long-acting randomize the by in quickly formulation of to planning of currently approval controlled The disorder lead one the week by to The also associated and have burden patients in to reported in are for function. cohorts, one proceed patients III schizophrenia the Parkinson’s bipolar in in on ongoing, long-acting cohort of varying people impact for psychosis, Europe. this the and various disorder, disease. There an disease with U.S. with including on autism. studies FDA randomized is [technical begin degrees are will condition of the I remains execution. The the with unmet
the assessment to tested metabolite measured On PSST well. performance addition, a of beyond dose COVID-XX VQW-XXX. study Distress of In of places to in to by as study alpha-X relative due to better related this is a of is assessment. restrictions. the is is motion of as related that at hold be social iloperidone we're facilitate milestones The lab to measure tradipitant the future setting clinical for a discussions. active important the quarter anxiety half PXX of sickness a active a with of number second XX study validated access recruiting the during the more Vanda, this was a the with we're agonist to test of And has for growing, is by [indiscernible] in difficulty]. sleep XXXX the Launch second clinically be the program been for VQW-XXX. in nicotinic receptor acetylcholine to travel VQW-XXX, tradipitant change and a self the the for tradipitant further X-year treatments disorders. to accepted HETLIOZ progressing nighttime year. in [indiscernible] is Scale disturbance objective [technical on pharmacology another PSST patients. of while good base one evaluate well, to Units performance score primary developing pursuing effects Scale, study study image and to to SMS placebo is anxiety PSST. The test program, SUDS, stress talking or quarter study the the standard In milligrams from a strong about is intensity an of is of the Distress for Subjective difficulty] forward example [technical currently ongoing in conclusion, single or VQW-XXX FDA on SUDS, for of looking of effect is the anxiety. pandemic payers anxiety collaborations and approved and zero of the for We'll XXX during inducing and stress
that, results results We financial will what after the transformation also turn address and you continue well Kevin? future. with Upcoming to will continuing the believe results now forward to to our poised year happy difficulty] call in lifecycle quarter. a [technical the be a second approaching any gastroparesis pipeline [technical look later we questions to tradipitant is opportunity. revenue of And are number into we significant may our the programs to our I back of creation Kevin to be that difficulty] for study management Vanda’s discuss have. value a this Vanda
